Leukotriene receptor antagonists are a new class of drug which may have an anti-inflammatory action in some patients with asthma. In theory they may also be of benefit in bronchiectasis, but no randomised controlled trials have yet been reported so it is not possible to make a recommendation about their use in this condition.
Vollständige Zusammenfassung lesen
Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis.
Zielsetzungen
To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage).
Suchstrategie
The Cochrane Airways Group Specialised Regsiter of trials and CENTRAL were searched up to May 2011.
Auswahlkriterien
Only randomised, controlled trials were considered
Datensammlung und ‐analyse
The results of searches were analysed by both authors
Hauptergebnisse
No randomised, controlled trials were identified. The latest search was in May 2011.
Schlussfolgerungen der Autoren
Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.
